184 related articles for article (PubMed ID: 12469933)
1. High-dose interleukin-2 in metastatic disease: renal cell carcinoma and melanoma.
Dutcher J
Oncology (Williston Park); 2002 Nov; 16(11 Suppl 13):3. PubMed ID: 12469933
[No Abstract] [Full Text] [Related]
2. Clinical pathways for managing patients receiving interleukin 2.
Mavroukakis SA; Muehlbauer PM; White RL; Schwartzentruber DJ
Clin J Oncol Nurs; 2001; 5(5):207-17. PubMed ID: 11905416
[TBL] [Abstract][Full Text] [Related]
3. Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma.
Dutcher JP
Oncology (Williston Park); 2002 Nov; 16(11 Suppl 13):4-10. PubMed ID: 12469934
[TBL] [Abstract][Full Text] [Related]
4. High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard.
Dutcher JP
Oncology (Williston Park); 2011 Apr; 25(5):427-8. PubMed ID: 21710841
[No Abstract] [Full Text] [Related]
5. CD4+CD25highFOXP3+ regulatory T cells in peripheral blood are primarily of effector memory phenotype.
Beyer M; Schultze JL
J Clin Oncol; 2007 Jun; 25(18):2628-30; author reply 2630-2. PubMed ID: 17577047
[No Abstract] [Full Text] [Related]
6. Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer.
Acquavella N; Kluger H; Rhee J; Farber L; Tara H; Ariyan S; Narayan D; Kelly W; Sznol M
J Immunother; 2008; 31(6):569-76. PubMed ID: 18528297
[TBL] [Abstract][Full Text] [Related]
7. Recurring cutaneous eruption in a patient with metastatic renal cell carcinoma being treated with high-dose interleukin 2.
O'Reilly F; Feldman E; Yang J; Hwu P; Turner ML
J Am Acad Dermatol; 2003 Apr; 48(4):602-4. PubMed ID: 12664026
[No Abstract] [Full Text] [Related]
8. Renal-cell carcinoma.
Vincenzi B; Santini D; Tonini G
N Engl J Med; 2006 Mar; 354(10):1095-6; author reply 1095-6. PubMed ID: 16528812
[No Abstract] [Full Text] [Related]
9. [Regional immunotherapy of metastatic renal cell carcinoma].
Heinzer H; Huland E; Huland H
Urologe A; 2002 May; 41(3):239-48. PubMed ID: 12132273
[TBL] [Abstract][Full Text] [Related]
10. Increased disease activity in a patient with sarcoidosis after high dose interleukin 2 treatment for metastatic renal cancer.
Logan TF; Bensadoun ES
Thorax; 2005 Jul; 60(7):610-1. PubMed ID: 15994271
[TBL] [Abstract][Full Text] [Related]
11. Biotherapy skin reaction.
Newton S; Jackowski C; Marrs J
Clin J Oncol Nurs; 2002; 6(3):181-2. PubMed ID: 11998617
[No Abstract] [Full Text] [Related]
12. A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor.
McDermott DF; Trehu EG; Mier JW; Sorce D; Rand W; Ronayne L; Kappler K; Clancy M; Klempner M; Atkins MB
Clin Cancer Res; 1998 May; 4(5):1203-13. PubMed ID: 9607578
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-2.
Med Lett Drugs Ther; 1990 Sep; 32(826):85-6. PubMed ID: 2202892
[No Abstract] [Full Text] [Related]
14. Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy.
Kirkwood JM; Tarhini AA
J Clin Oncol; 2009 Jun; 27(16):2583-5. PubMed ID: 19364958
[No Abstract] [Full Text] [Related]
15. [Clinical study on recombinant human interleukin-2 (Proleukin) in the treatment of metastatic renal cell carcinoma].
Sheng XN; Li JL; Guo J; Zhao XH; Zhu J; Chu DT
Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):129-33. PubMed ID: 18646697
[TBL] [Abstract][Full Text] [Related]
16. High-dose interleukin-2 immunotherapy is safe for patients with metastatic renal cell carcinoma on dialysis.
Brusky JP; Gailani F; Pathak A; Patel H; Aboseif S
BJU Int; 2006 Feb; 97(2):279-80. PubMed ID: 16430629
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma.
Hashmi MH; Van Veldhuizen PJ
Expert Opin Biol Ther; 2010 May; 10(5):807-17. PubMed ID: 20384523
[TBL] [Abstract][Full Text] [Related]
18. Progressive anemia following combination therapy with interferon-alpha and interleukin-2 in a patient with metastatic renal cell carcinoma.
Hosokawa Y; Kishino T; Ono T; Oyama N; Hayashi K; Momose H
Int J Urol; 2004 Oct; 11(10):906-8. PubMed ID: 15479299
[TBL] [Abstract][Full Text] [Related]
19. Clinical and safety profile of high-dose interleukin-2 treatment in elderly patients with metastatic melanoma and renal cell carcinoma.
Clark JM; Kelley B; Titze J; Fung H; Maciejewski J; Nathan S; Rich E; Basu S; Kaufman HL
Oncology; 2013; 84(2):123-6. PubMed ID: 23235386
[TBL] [Abstract][Full Text] [Related]
20. Rigor prophylaxis in stage IV melanoma and renal cell carcinoma patients treated with high dose IL-2.
Khong B; Lawson BO; Ma J; McGovern C; Van Atta JK; Ray A; Khong HT
BMC Cancer; 2018 Oct; 18(1):1007. PubMed ID: 30342473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]